Introgen has announced that it has recently filed applications with the FDA to get approval for its new gene therapy for cancer. The gene therapy is called Advexin. If this passes FDA inspection, it will become the first gene therapy to be approved in this country. Gene therapy has taken a considerable amount of time to get off the ground. There have been many problems that had to be overcome, before they reached this stage of progress.Introgen uses a modified adenovirus that delivers the TP53 gene to cancer cells. P53 is a protein that causes apoptosis or cell death. This allows scientists to selectively kill off cancer cells, presumably with minimal damage to other cells. A similar gene therapy has already been approved in China. Finding better cures for cancer will go a long way in improving anti-aging prospects as cancer is a major compotent of age related deaths.
Here's some info from Introgen's website.
"Introgen utilizes a variety of platform technologies to develop novel therapies for cancer. Each of these proprietary technologies elicits its therapeutic effects via a highly targeted mechanism of action. This diversity of platforms provides Introgen with multiple approaches to treating cancer, which include:
Delivering cancer-fighting tumor suppressors to cancer
cells
Stimulating the patient’s immune system to attack cancer
cells
Targeting viral replication and cell death to cancer cells
Each platform is designed to produce maximal cancer cell killing with minimal damage to healthy tissue. These targeted therapies have the potential to transform the landscape of cancer care and may lead to novel treatments for diseases with significant unmet medical need. In addition to supporting a variety of cancer-killing approaches, these diverse technologies also provide Introgen with multiple product development opportunities"


